Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marco Spinsanti

Showing results (1-10 of 9) with videos related to

Pageof 1
Sort By:
Frontiers in Cellular and Infection Microbiology|May 10, 2024
Editorial: Bacterial surface polymersTarcisio Brignoli, Marco Spinsanti, Maisem Laabei, et al.
Plos One|June 4, 2014
In depth analysis of the Helicobacter pylori cag pathogenicity island transcriptional responsesAndrea Vannini, Davide Roncarati, Marco Spinsanti, et al.
Microorganisms|April 23, 2022
Multilayer Regulation of <i>Neisseria meningitidis</i> NHBA at Physiologically Relevant TemperaturesSara Borghi, Ana Antunes, Andreas F Haag, et al.
Plos Pathogens|March 26, 2021
Deconvolution of intergenic polymorphisms determining high expression of Factor H binding protein in meningococcus and their association with invasive diseaseMarco Spinsanti, Tarcisio Brignoli, Margherita Bodini, et al.
Hematological Oncology|May 17, 2017
Comparison of JAK2<sup>V617F</sup> -positive essential thrombocythaemia and early primary myelofibrosis: The impact of mutation burden and histologyRoberto Latagliata, Nicola Polverelli, Alessia Tieghi, et al.
Hematological Oncology|May 18, 2017
Efficacy and safety of ruxolitinib in intermediate-1 IPSS risk myelofibrosis patients: Results from an independent studyFrancesca Palandri, Mario Tiribelli, Giulia Benevolo, et al.
Proceedings of the National Academy of Sciences of the United States of America|February 19, 2016
Expression of factor H binding protein in meningococcal strains can vary at least 15-fold and is genetically determinedMassimiliano Biagini, Marco Spinsanti, Gabriella De Angelis, et al.
NPJ Vaccines|July 5, 2025
A novel GMMA-based gonococcal vaccine demonstrates functional immune responses in miceMarco Spinsanti, Elisabetta Monaci, Giacomo Romagnoli, et al.
Oncotarget|November 8, 2017
Baseline factors associated with response to ruxolitinib: an independent study on 408 patients with myelofibrosisFrancesca Palandri, Giuseppe Alberto Palumbo, Massimiliano Bonifacio, et al.
Pageof 1

Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
Frontiers in Cellular and Infection Microbiology|May 10, 2024
Editorial: Bacterial surface polymersTarcisio Brignoli, Marco Spinsanti, Maisem Laabei, et al.
Plos One|June 4, 2014
In depth analysis of the Helicobacter pylori cag pathogenicity island transcriptional responsesAndrea Vannini, Davide Roncarati, Marco Spinsanti, et al.
Microorganisms|April 23, 2022
Multilayer Regulation of <i>Neisseria meningitidis</i> NHBA at Physiologically Relevant TemperaturesSara Borghi, Ana Antunes, Andreas F Haag, et al.
Plos Pathogens|March 26, 2021
Deconvolution of intergenic polymorphisms determining high expression of Factor H binding protein in meningococcus and their association with invasive diseaseMarco Spinsanti, Tarcisio Brignoli, Margherita Bodini, et al.
Hematological Oncology|May 17, 2017
Comparison of JAK2<sup>V617F</sup> -positive essential thrombocythaemia and early primary myelofibrosis: The impact of mutation burden and histologyRoberto Latagliata, Nicola Polverelli, Alessia Tieghi, et al.
Hematological Oncology|May 18, 2017
Efficacy and safety of ruxolitinib in intermediate-1 IPSS risk myelofibrosis patients: Results from an independent studyFrancesca Palandri, Mario Tiribelli, Giulia Benevolo, et al.
Proceedings of the National Academy of Sciences of the United States of America|February 19, 2016
Expression of factor H binding protein in meningococcal strains can vary at least 15-fold and is genetically determinedMassimiliano Biagini, Marco Spinsanti, Gabriella De Angelis, et al.
NPJ Vaccines|July 5, 2025
A novel GMMA-based gonococcal vaccine demonstrates functional immune responses in miceMarco Spinsanti, Elisabetta Monaci, Giacomo Romagnoli, et al.
Oncotarget|November 8, 2017
Baseline factors associated with response to ruxolitinib: an independent study on 408 patients with myelofibrosisFrancesca Palandri, Giuseppe Alberto Palumbo, Massimiliano Bonifacio, et al.
Pageof 1